A modified murine model based on hydrodynamic injection for the analysis of chronic human hepatitis B virus infection

Qin,Bo; Tu,Chunyu; Zhang,Bo; He,Tingting; Fu,Lijun; Xu,Wenying

doi:10.3892/mmr.2013.1732

A modified murine model based on hydrodynamic injection for the analysis of chronic human hepatitis B virus infection

Authors:
- Bo Qin
- Chunyu Tu
- Bo Zhang
- Tingting He
- Lijun Fu
- Wenying Xu
View Affiliations

Affiliations: Shaoxing Center for Disease Control and Prevention, Shaoxing, Zhejiang, P.R. China, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, P.R. China
Published online on: October 14, 2013 https://doi.org/10.3892/mmr.2013.1732
Pages: 1677-1682

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatitis B virus (HBV) is a persistent pathogen that causes acute and chronic necroinflammatory liver disease and is attributable to ~1 million deaths per year. In the present study, a conventional murine model was introduced based on the hydrodynamic injection of engineered replication‑competent HBV DNA into the tail veins of C57BL/6 mice. In a previous study, nine in‑frame ATG (start) codons in the S open reading frame (S1‑S9) were analyzed. The highly conserved ATG S5 was mutated to ACG by T378C, which led to the substitution sM75T and inhibition of the production and secretion of the hepatitis B surface antigen (HBsAg), and subsequent inhibition of HBV replication. In the present study, T378C was introduced into the pAAV‑HBV1.3 plasmid and was confirmed to affect HBsAg production and secretion, and HBV replication in vivo, which was in agreement with the previous in vitro results. Furthermore, the murine model was improved by co‑injection of the replication‑competent HBV plasmid DNA with Lipofectamine 2000 (LP). In this model, LP not only significantly enhanced HBV replication in mice, but also upregulated the expression of HBsAg and the hepatitis B core antigen. The current modified murine model was superior to the conventional murine HBV model based on HBV challenge by hydrodynamic injection.

View Figures

View References

1	Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 11:97–107. 2004. View Article : Google Scholar : PubMed/NCBI
2	Lee WM: Hepatitis B virus infection. N Engl J Med. 337:1733–1745. 1997. View Article : Google Scholar : PubMed/NCBI
3	Yan H, Zhong G, Xu G, et al: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 1:e000492012.
4	Paganelli M, Dallmeier K, Nyabi O, et al: Differentiated umbilical cord matrix stem cells as a new in vitro model to study early events during hepatitis B infection. Hepatology. 57:59–69. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yan Z, Tan W, Dan Y, et al: Estrogen receptor alpha gene polymorphisms and risk of HBV-related acute liver failure in the Chinese population. BMC Med Genet. 13:492012. View Article : Google Scholar : PubMed/NCBI
6	Zoulim F and Locarnini S: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 137:1593–1608. 2009. View Article : Google Scholar : PubMed/NCBI
7	Liu F, Chen L, Yu DM, et al: Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut. 60:1269–1277. 2011. View Article : Google Scholar : PubMed/NCBI
8	Takehara T, Suzuki T, Ohkawa K, et al: Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J Hepatol. 44:267–274. 2006. View Article : Google Scholar : PubMed/NCBI
9	Lim W, Kwon SH, Cho H, et al: HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression. J Mol Med (Berl). 88:359–369. 2010. View Article : Google Scholar : PubMed/NCBI
10	Schinazi RF, Ilan E, Black PL, Yao X and Dagan S: Cell-based and animal models for hepatitis B and C viruses. Antivir Chem Chemother. 10:99–114. 1999. View Article : Google Scholar : PubMed/NCBI
11	Tang N, Huang AL, Zhang BQ, et al: Construction of recombinant eukaryotic expression plasmid containing 1.3-fold-overlength genome of HBV and its expression in HepG2 cells. Zhonghua Gan Zang Bing Za Zhi. 11:464–466. 2003.(In Chinese).
12	Huang LR, Wu HL, Chen PJ and Chen DS: An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA. 103:17862–17867. 2006. View Article : Google Scholar : PubMed/NCBI
13	Yin Y, Wu C, Song J, et al: DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic. PloS One. 6:e225242011. View Article : Google Scholar : PubMed/NCBI
14	Qin B, Budeus B, Cao L, et al: The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Res. 97:93–100. 2013. View Article : Google Scholar : PubMed/NCBI
15	Mizokami M, Orito E, Ohba K, Ikeo K, Lau JY and Gojobori T: Constrained evolution with respect to gene overlap of hepatitis B virus. J Mol Evol. 44(Suppl 1): S83–S90. 1997. View Article : Google Scholar : PubMed/NCBI
16	Gao W and Hu J: Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol. 81:6164–6174. 2007. View Article : Google Scholar : PubMed/NCBI
17	Miller RH, Kaneko S, Chung CT, Girones R and Purcell RH: Compact organization of the hepatitis B virus genome. Hepatology. 9:322–327. 1989. View Article : Google Scholar : PubMed/NCBI
18	Carman WF: The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 4(Suppl 1): 11–20. 1997. View Article : Google Scholar : PubMed/NCBI
19	Qiu J, Qin B, Rayner S, et al: Novel evidence suggests Hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virol Sin. 26:131–138. 2011. View Article : Google Scholar : PubMed/NCBI
20	Qin B, He T, Chen Z, Xu W, Pan G and Tu C: A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus. Int J Mol Med. 31:975–981. 2013.PubMed/NCBI
21	Hu J and Boyer M: Hepatitis B virus reverse transcriptase and epsilon RNA sequences required for specific interaction in vitro. J Virol. 80:2141–2150. 2006. View Article : Google Scholar : PubMed/NCBI
22	Hu J, Flores D, Toft D, Wang X and Nguyen D: Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. J Virol. 78:13122–13131. 2004. View Article : Google Scholar
23	Chua PK, Wang RY, Lin MH, Masuda T, Suk FM and Shih C: Reduced secretion of virions and hepatitis B virus (HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus. J Virol. 79:13483–13496. 2005. View Article : Google Scholar